Company / Cash & Equivalents
LIPELLA PHARMACEUTICALS INC. Cash & Equivalents History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$2.2M
FY2024
5-year range
$2.2M / $5.1M
FY2022-FY2024
Trend
-33.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $5M to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2024.
Declined from $5M to $2M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, cash & equivalents decreased 33.7% year-over-year.
Company context
Key Data Points
- Altman Z-Score -8.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $2.2M | -33.7% |
| FY2023 | $3.3M | -35.7% |
| FY2022 | $5.1M | - |
As of FY2024 · SEC Form 10-K · Last checked Jun 29, 2026